Contributions
Abstract: EP1402
Type: ePoster
Abstract Category: Clinical aspects of MS - 8 Clinical assessment tools
Background: Multiple Sclerosis (MS) is a chronic neurological disease that mainly affects young adults, adversely impacting on many aspects of their life. Notoriously, mood disorders may be associated with abnormalities in biological rhythms (BR), with changes in sleeping and eating patterns as well as in social and daily activities. Psychiatric comorbidities are very common among MS patients (Carta et al., 2014), while the presence of dysregulation of BR has not been adequately explored.
This study aimed to investigate the relationships between circadian BR disturbance with MS clinical features and psychiatric comorbidity. In addition, we evaluated the weight of BR impairment on patients' quality of life (QoL).
Methods: MS patients, diagnosed according to McDonald criteria, were enrolled and clinical features were collected.
DMS IV psychiatric diagnoses were determined by ANTAS-SCID interview (Carta et al., 2010).
The Italian Version of the BRIAN questionnaire was used to assess abnormalities in BR (sleep, eating, activities and social rhythms) (Moro et al., 2010). QoL was evaluated with the Short Form Health Survey (SF-12) (Ware et al., 1996). Descriptive statistics, hierarchical regression analyses, t-test, and the Pearson's correlation were conducted.
Results: The sample included 178 MS patients (61 male); of these 38/178 had progressive course. Mean value for the disease duration was 10.5 years, while mean EDSS was 2.5. The diagnosis of unipolar depression was established in 43/178 (24.1%) patients, and bipolar spectrum disorders in 32/178 (17.9%). BRIAN scores were respectively 43.6 and 34.4 in patients with and without moods disorders
(p < 0.001). Psychiatric comorbidity, in particular bipolar disorder, was the strongest determinant of BR dysregulation (p < 0.01), independent from MS clinical features (EDSS and disease duration). However, an association between BR impairment and EDSS score was observed (p < 0.01). In addition, BRIAN score was negatively associated with SF-12 score (r= -0.529; p < 0. 001).
Conclusions: Psychiatric comorbidities seem to strongly influence BR dysregulation in people living with MS. BRIAN questionnaire could be a useful tool in clinical practice to identify BR abnormalities also in MS, bearing in mind the impact of these abnormalities on QoL as well as their association with psychiatric comorbidities.
Keywords: biological rhythms abnormalities; BRIAN questionnaire; psychiatric comorbidities; quality of life.
Disclosure:
Dr. Lorefice received speaker fee from Teva and serves on scientific advisory boards for Biogen.
Dr. Fenu received honoraria for consultancy from Novartis and for speaking from Merck Serono and Teva.
Dr. Frau serves on scientific advisory boards for Biogen, received honoraria for speaking from Merck Serono and Teva.
Dr. Coghe received speaker fee from Teva and Almirall.
Professor Cocco and Marrosu have received honoraria for consultancy or speaking from Bayer, Biogen-Idec, Novartis, Sanofi-Genzyme, Serono and Teva.
Mrs Pitzalis and Professor Carta have nothing to disclose.
Abstract: EP1402
Type: ePoster
Abstract Category: Clinical aspects of MS - 8 Clinical assessment tools
Background: Multiple Sclerosis (MS) is a chronic neurological disease that mainly affects young adults, adversely impacting on many aspects of their life. Notoriously, mood disorders may be associated with abnormalities in biological rhythms (BR), with changes in sleeping and eating patterns as well as in social and daily activities. Psychiatric comorbidities are very common among MS patients (Carta et al., 2014), while the presence of dysregulation of BR has not been adequately explored.
This study aimed to investigate the relationships between circadian BR disturbance with MS clinical features and psychiatric comorbidity. In addition, we evaluated the weight of BR impairment on patients' quality of life (QoL).
Methods: MS patients, diagnosed according to McDonald criteria, were enrolled and clinical features were collected.
DMS IV psychiatric diagnoses were determined by ANTAS-SCID interview (Carta et al., 2010).
The Italian Version of the BRIAN questionnaire was used to assess abnormalities in BR (sleep, eating, activities and social rhythms) (Moro et al., 2010). QoL was evaluated with the Short Form Health Survey (SF-12) (Ware et al., 1996). Descriptive statistics, hierarchical regression analyses, t-test, and the Pearson's correlation were conducted.
Results: The sample included 178 MS patients (61 male); of these 38/178 had progressive course. Mean value for the disease duration was 10.5 years, while mean EDSS was 2.5. The diagnosis of unipolar depression was established in 43/178 (24.1%) patients, and bipolar spectrum disorders in 32/178 (17.9%). BRIAN scores were respectively 43.6 and 34.4 in patients with and without moods disorders
(p < 0.001). Psychiatric comorbidity, in particular bipolar disorder, was the strongest determinant of BR dysregulation (p < 0.01), independent from MS clinical features (EDSS and disease duration). However, an association between BR impairment and EDSS score was observed (p < 0.01). In addition, BRIAN score was negatively associated with SF-12 score (r= -0.529; p < 0. 001).
Conclusions: Psychiatric comorbidities seem to strongly influence BR dysregulation in people living with MS. BRIAN questionnaire could be a useful tool in clinical practice to identify BR abnormalities also in MS, bearing in mind the impact of these abnormalities on QoL as well as their association with psychiatric comorbidities.
Keywords: biological rhythms abnormalities; BRIAN questionnaire; psychiatric comorbidities; quality of life.
Disclosure:
Dr. Lorefice received speaker fee from Teva and serves on scientific advisory boards for Biogen.
Dr. Fenu received honoraria for consultancy from Novartis and for speaking from Merck Serono and Teva.
Dr. Frau serves on scientific advisory boards for Biogen, received honoraria for speaking from Merck Serono and Teva.
Dr. Coghe received speaker fee from Teva and Almirall.
Professor Cocco and Marrosu have received honoraria for consultancy or speaking from Bayer, Biogen-Idec, Novartis, Sanofi-Genzyme, Serono and Teva.
Mrs Pitzalis and Professor Carta have nothing to disclose.